Glenmark q2 concall update
India q2 was marginally up due to slowdown in derma and respiratory. Picking up in q3.
Usa gone below 100 mn usd again, 3 respiratory lajnches thru in licensing.
Europe doing exceptionally well and momentum to continue.
Row doing well and expected to continue
Margin impact due to gls divestment to be mitigated by reigning of R&D, capex,operational leverage and reduction of intrest cost
Munroe starting engg batches,followed by validation batches and then commercial launch.
Astria payment has come in q3.
Update from ichnos site
Isb 1342 trial stopped and will be outlicensed.
Ichnos targeting ipo in 12 months time.
| Subscribe To Our Free Newsletter |
